Literature DB >> 26908618

Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice.

Susanna Mantovani1, Richard Gordon2, Rui Li2, Daniel C Christie2, Vinod Kumar2, Trent M Woodruff3.   

Abstract

Huntington's disease (HD) is an incurable neurodegenerative condition characterized by progressive motor and cognitive dysfunction, and depletion of neurons in the striatum. Recently, BACHD transgenic mice expressing the full-length human huntingtin gene have been generated, which recapitulate some of the motor and cognitive deficits seen in HD. In this study, we carried out a series of extensive behavioural and neuropathological tests on BACHD mice, to validate this mouse for preclinical research. Transgenic C57BL/6J BACHD and litter-matched wild-type mice were examined in a battery of motor and cognitive function tests at regular intervals up to 12 months of age. Brains from these mice were also analysed for signs of neurodegeneration and striatal and cortical volume sizes compared using anatomic 16.4T magnetic resonance imaging (MRI) brain scans. BACHD mice showed progressive motor impairments on rotarod and balance beam tests starting from 3 months of age, were hypoactive in the open field tests starting from 6 months of age, however, showed no alterations in gait and grip strength at any age. Surprisingly, despite these distinct motor deficits, no signs of neuronal loss, gliosis or blood-brain barrier degeneration were observed in the striatum of 12-month-old mice. MRI brain scans confirmed no reduction in striatal or cortical volumes at 12 months of age, and BACHD mice had a normal lifespan. These results demonstrate that classical Huntington's-like motor impairments seen in this transgenic model, do not occur due to degeneration of the striatum, and thus caution against the use of this model for preclinical studies into HD.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2016        PMID: 26908618     DOI: 10.1093/hmg/ddw050

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.

Authors:  Amber L Southwell; Amy Smith-Dijak; Chris Kay; Marja Sepers; Erika B Villanueva; Matthew P Parsons; Yuanyun Xie; Lisa Anderson; Boguslaw Felczak; Sabine Waltl; Seunghyun Ko; Daphne Cheung; Louisa Dal Cengio; Ramy Slama; Eugenia Petoukhov; Lynn A Raymond; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2016-07-04       Impact factor: 6.150

2.  Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington's disease.

Authors:  Jeremy F Atherton; Eileen L McIver; Matthew Rm Mullen; David L Wokosin; D James Surmeier; Mark D Bevan
Journal:  Elife       Date:  2016-12-20       Impact factor: 8.140

3.  A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.

Authors:  Danielle A Simmons; Nadia P Belichenko; Ellen C Ford; Sarah Semaan; Marie Monbureau; Sruti Aiyaswamy; Cameron M Holman; Christina Condon; Mehrdad Shamloo; Stephen M Massa; Frank M Longo
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

4.  Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease.

Authors:  Alba Di Pardo; Enrico Amico; Francesco Scalabrì; Giuseppe Pepe; Salvatore Castaldo; Francesca Elifani; Luca Capocci; Claudia De Sanctis; Laura Comerci; Francesco Pompeo; Maurizio D'Esposito; Stefania Filosa; Stefania Crispi; Vittorio Maglione
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

5.  Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease.

Authors:  Marie Rodinova; Jana Krizova; Hana Stufkova; Bozena Bohuslavova; Georgina Askeland; Zaneta Dosoudilova; Stefan Juhas; Jana Juhasova; Zdenka Ellederova; Jiri Zeman; Lars Eide; Jan Motlik; Hana Hansikova
Journal:  Dis Model Mech       Date:  2019-07-26       Impact factor: 5.758

6.  Abnormalities in the Motor Unit of a Fast-Twitch Lower Limb Skeletal Muscle in Huntington's Disease.

Authors:  Priscila Aparecida Costa Valadão; Bárbara Campos de Aragão; Jéssica Neves Andrade; Matheus Proença S Magalhães-Gomes; Giselle Foureaux; Julliane Vasconcelos Joviano-Santos; José Carlos Nogueira; Thatiane Cristina Gonçalves Machado; Itamar Couto Guedes de Jesus; Julia Meireles Nogueira; Rayan Silva de Paula; Luisa Peixoto; Fabíola Mara Ribeiro; Juan Carlos Tapia; ÉriKa Cristina Jorge; Silvia Guatimosim; Cristina Guatimosim
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

Review 7.  Molecular Mechanisms Underlying Muscle Wasting in Huntington's Disease.

Authors:  Manuela Bozzi; Francesca Sciandra
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

8.  Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Authors:  Yunping Deng; Hongbing Wang; Marion Joni; Radhika Sekhri; Anton Reiner
Journal:  J Comp Neurol       Date:  2020-09-20       Impact factor: 3.215

9.  Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model.

Authors:  Rachel Y Cheong; Barbara Baldo; Muhammad U Sajjad; Deniz Kirik; Åsa Petersén
Journal:  Neuropathol Appl Neurobiol       Date:  2021-01-12       Impact factor: 8.090

10.  TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.

Authors:  Danielle A Simmons; Michelle L James; Nadia P Belichenko; Sarah Semaan; Christina Condon; Jason Kuan; Adam J Shuhendler; Zheng Miao; Frederick T Chin; Frank M Longo
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.